GlassScriptPhysician profile
Suzann Szewczak
NPI 1114962800
$2,272.15
in general payments reported to CMS, 2019-2025
29 companies · $99.00 in 2025
The $99.00 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $905 · 2020: $290 · 2022: $76.63 · 2023: $572 · 2024: $330 · 2025: $99.00.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,001.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,000.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $383.57 | 2019-2025 | |
| Abbvie INC. | $357.16 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Novo Nordisk INC | $311.97 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Glaxosmithkline, LLC. | $148.41 | 2019-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $115.59 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $114.93 | 2019 | |
| Amgen INC. | $96.20 | 2019-2024 | Otezla, Repatha, Evenity |
| Astrazeneca Pharmaceuticals LP | $80.74 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $74.76 | 2019-2022 | |
| Astellas Pharma US INC | $72.55 | 2019-2023 | Myrbetriq |
| Janssen Pharmaceuticals, INC | $61.69 | 2019-2022 | |
| Lilly USA, LLC | $51.20 | 2019-2022 | |
| Amarin Pharma, INC. | $49.36 | 2019-2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $40.84 | 2023 | |
| Exact Sciences Corporation | $33.86 | 2023 | Cologuard Collection Kit |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $33.71 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.96 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $28.92 | 2020-2024 | |
| Allergan, INC. | $26.35 | 2019-2020 | |
| Phathom Pharmaceuticals, INC. | $23.74 | 2024 | Voquezna |
| Bausch Health US, LLC | $20.09 | 2019 | |
| Nalpropion Pharmaceuticals LLC | $19.09 | 2019 | |
| Lundbeck LLC | $15.89 | 2024 | Rexulti |
| Biogen, INC. | $14.78 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.61 | 2019 | |
| Currax Pharmaceuticals LLC | $12.90 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.83 | 2020 | |
| Arbor Pharmaceuticals, INC. | $12.57 | 2020 | |
| Shire North American Group INC | $11.88 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Suzann Szewczak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.